U.S. Markets open in 8 hrs 42 mins

Why This Biotech Stock Cratered 68% On Its Gene Therapy Study

ALLISON GATLIN
Why This Biotech Stock Cratered 68% On Its Gene Therapy Study

Solid Biosciences crashed Thursday after its experimental gene therapy disappointed in a study of Duchenne muscular dystrophy patients. Sarepta Therapeutics, a rival, saw shares pop.